The venus flytrap of periplasmic binding proteins: An ancient protein module present in multiple drug receptors
Journal Title: The AAPS Journal - Year 1999, Vol 1, Issue 2
Abstract
Located between the inner and outer membranes of Gram-negative bacteria, periplasmic binding proteins (PBPs) scavenge or sense diverse nutrients in the environment by coupling to transporters or chemotaxis receptors in the inner membrane. Their three-dimensional structures have been deduced in atomic detail with the use of X-ray crystallography, both in the free and liganded state. PBPs consist of two large lobes that close around the bound ligand, resembling a Venus flytrap. This architecture is reiterated in transcriptional regulators, such as the lac repressors. In the process of evolution, genes encoding the PBPs have fused with genes for integral membrane proteins. Thus, diverse mammalian receptors contain extracellular ligand binding domains that are homologous to the PBPs; these include glutamate/glycine-gated ion channels such as the NMDA receptor, G protein-coupled receptors, including metabotropic glutamate, GABA-B, calcium sensing, and pheromone receptors, and atrial natriuretic peptide-guanylate cyclase receptors. Many of these receptors are promising drug targets. On the basis of homology to PBPs and a recently resolved crystal structure of the extracellular binding domain of a glutamate receptor ion channel, it is possible to construct three-dimensional models of their ligand binding domains. Together with the extensive information available on the mechanism of ligand binding to PBPs, such models can serve as a guide in drug discovery.
Authors and Affiliations
Christian B. Felder, Richard C. Graul, Alan Y. Lee, Hans-Peter Merkle, Wolfgang Sadee
Keywords
Related Articles
- EP ID EP682104
- DOI 10.1208/ps010202
- Views 90
- Downloads 0
Human Cannabinoid 1 GPCR C-Terminal Domain Interacts with Bilayer Phospholipids to Modulate the Structure of its Membrane Environment
G protein-coupled receptors (GPCRs) play critical physiological and therapeutic roles. The human cannabinoid 1 GPCR (hCB1) is a prime pharmacotherapeutic target for addiction and cardiometabolic disease. Our prior biophy...
Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs
During the last decades, the importance of modeling and simulation in clinical drug development, with the goal to qualitatively and quantitatively assess and understand mechanisms of pharmacokinetic processes, has strong...
Assessing the cost-effectiveness of pharmacogenomics
The use of pharmacogenomics to individualize drug therapy offers the potential to improve drug effectiveness, reduce adverse side effects, and provide cost-effective pharmaceutical care. However, the combinations of dise...
Clinical Relevance of Dissolution Testing in Quality by Design
Quality by design (QbD) has recently been introduced in pharmaceutical product development in a regulatory context and the process of implementing such concepts in the drug approval process is presently on-going. This ha...
Statistical Comparison of Dissolution Profiles to Predict the Bioequivalence of Extended Release Formulations
The online version of this article (doi:10.1208/s12248-014-9615-6) contains supplementary material, which is available to authorized users.